Modality
ERT
MOA
TROP-2 ADC
Target
MET
Pathway
RAS/MAPK
MCCPBC
Development Pipeline
Preclinical
Nov 2020
→ Mar 2026
PreclinicalCurrent
NCT03913975
1,484 pts·MCC
2023-09→TBD·Recruiting
NCT04006434
1,215 pts·MCC
2020-11→2026-03·Recruiting
2,699 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-211w agoInterim· MCC
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Recruit…
Preclinical
Recruit…
Catalysts
Interim
2026-03-21 · 1w ago
MCC
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03913975 | Preclinical | MCC | Recruiting | 1484 | FEV1 |
| NCT04006434 | Preclinical | MCC | Recruiting | 1215 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP |